United States Patent 7,816,383: Scope, Claim Strength, and Landscape for Pirfenidone-Plus-Fluvoxamine Interaction Avoidance
What does US 7,816,383 claim cover?
US 7,816,383 is a method-of-treatment patent focused on managing pirfenidone therapy when a patient is also treated with fluvoxamine, centering on avoiding co-administration or discontinuing fluvoxamine before starting pirfenidone. The claims repeatedly tie this interaction management to CYP1A2-related exposure increases and the clinical regimen for idiopathic pulmonary fibrosis (IPF).
Core protected acts (what is “in scope”)
The invention protects physician/patient instructions and treatment execution steps that accomplish one or more of the following:
- Pirfenidone administration with fluvoxamine avoided
- Provide pirfenidone at a therapeutically effective dose while avoiding fluvoxamine co-administration when the patient is in need of fluvoxamine therapy (claim 1; claim 11 and dependent advice claims).
- Fluvoxamine discontinuation sequencing
- Discontinue fluvoxamine first, then start pirfenidone (claims 5-10).
- Dose and schedule specificity for pirfenidone
- Daily dosage specified as 2400 mg or 2403 mg/day (claims 3, 7, and incorporated into claim 11 dependent scope).
- Or an administration form specifying 800 or 801 mg three times per day with food (claims 4, 8).
- Patient counseling/advice as an actionable method
- The claims include multiple dependent claim types that are effectively “instructional” (advising patients to avoid/discontinue fluvoxamine; advising about other inhibitor classes; contraindication framing; exposure arithmetic; and caution instructions for strong CYP1A2 inhibitors) (claims 11-20).
Condition and therapeutic area (who is “in scope”)
The claims focus on:
- Patients with IPF (claims 2, 6, and in claim 11).
The scope therefore is not a broad generic “drug interaction management” patent across all indications. It is anchored to pirfenidone in IPF and a defined interaction with fluvoxamine.
How broad is claim coverage across patient populations?
Claim 1 and claim 5: broadest independent claims
- Claim 1: covers any patient “in need” of both therapies where the method avoids co-administration of fluvoxamine while administering a therapeutically effective amount of pirfenidone. IPF is not required in claim 1.
- Claim 5: covers the sequencing method: discontinue fluvoxamine and then administer pirfenidone. IPF is not required in claim 5.
Claim 2 / claim 6: IPF-limited dependent coverage
- IPF limitation narrows claims 2 and 6, but these dependent forms still establish that IPF-specific versions exist.
Claim 11: IPF plus “advice” content
- Claim 11 is a second independent method framing that explicitly requires IPF and combines:
- daily dosing (2400 or 2403 mg/day),
- avoidance of fluvoxamine co-administration, and
- any one or more “advising” elements (a)-(f), which makes it broader in a different way: it does not require a particular counseling phrasing so long as the patient is advised in one or more listed ways.
Practical breadth conclusion:
US 7,816,383 covers at least two tiers:
- a sequencing/avoidance method tier applicable beyond IPF (claims 1 and 5), and
- an IPF plus dosing plus counseling tier that can be easier to enforce in real-world clinical instructions (claim 11 with dependent counseling sub-claims).
What are the key claim elements that define infringement risk?
1) Avoidance of fluvoxamine co-administration (the “gate”)
- The method requires that fluvoxamine is not co-administered during pirfenidone therapy when the patient is in need of fluvoxamine therapy (claim 1; claim 11).
This is the central operational requirement. A design-around that still uses fluvoxamine continuously during pirfenidone therapy is the highest risk of falling into the literal scope.
2) Discontinuation timing (the “window”)
Claims 9 and 10 add explicit windows:
- Discontinue fluvoxamine within 1 month prior to starting pirfenidone (claim 9).
- Discontinue fluvoxamine within 2 weeks prior to starting pirfenidone (claim 10).
A provider who stops fluvoxamine earlier than 1 month might attempt to argue outside these specific dependent windows. But note the independent sequencing claim (claim 5) is not limited to those windows.
3) Pirfenidone dose and regimen specifics
The patent contains dose-specific dependents:
- 2400 mg or 2403 mg/day (claims 3, 7, and in claim 11).
- 800 or 801 mg TID with food (claims 4, 8).
These dependents create enforcement leverage if the infringing regimen is consistent with marketed IPF titration/maintenance patterns and drug labeling language.
4) Counseling/advice statements (the “behavioral” infringement pathway)
Claims 11-20 explicitly include advising the patient about:
- contraindication/avoidance of fluvoxamine (claims 12 and 15),
- alteration of efficacy or adverse reactions due to CYP inhibitor co-therapy (claims 13-14),
- the numeric exposure increase evidence: “6-fold increase in exposure” (claims 16-17), and
- additional CYP1A2 caution and actions (claims 18-20).
This transforms the patent from purely “what clinicians prescribe” to “what clinicians tell patients and document,” raising real-world enforceability where medication counseling and interaction warnings appear in records or discharge instructions.
How strong is the “interaction science” portion of the claims?
The claims embed specific mechanistic and exposure facts:
- Co-administration of pirfenidone and fluvoxamine results in a 6-fold increase in exposure (claims 11(f), 16).
- Co-administration results in a 2-fold increase in average peak serum concentration (Cmax) (claim 17).
They also incorporate CYP inhibitor cautions:
- Strong CYP1A2 inhibitors should be used with caution due to reduced clearance (claim 18).
- Avoid or discontinue a strong CYP1A2 inhibitor (claims 19-20).
From a patent scope standpoint, these numerics act as claim anchors. A party that avoids fluvoxamine co-administration might still argue they are outside the counseling forms that require the exposure statements. But the strongest literal risk arises if the counseling includes those exact interaction conclusions.
Claim-by-claim scope map (what each claim adds)
| Claim |
Additional requirement beyond prior claim set |
Practical scope impact |
| 1 |
Avoid fluvoxamine co-administration while administering therapeutically effective pirfenidone |
Broadest method: requires avoidance, not timing or dose specifics |
| 2 |
Patient has IPF |
Narrows population |
| 3 |
Daily pirfenidone dose is 2400 mg or 2403 mg |
Narrows regimen |
| 4 |
800 or 801 mg TID with food |
Narrows regimen form |
| 5 |
Discontinue fluvoxamine first, then administer pirfenidone |
Sequencing-based enforceability |
| 6 |
IPF |
Narrows population |
| 7 |
2400 or 2403 mg/day |
Narrows regimen |
| 8 |
800 or 801 mg TID with food |
Narrows regimen form |
| 9 |
Discontinue fluvoxamine within 1 month prior |
Adds dependent timing window |
| 10 |
Discontinue fluvoxamine within 2 weeks prior |
Adds tighter dependent timing window |
| 11 |
IPF + daily dose 2400/2403 + avoid fluvoxamine co-administration + “advising” (a)-(f) |
Broad enforcement via counseling plus dose/avoidance |
| 12 |
Advising to avoid or discontinue fluvoxamine |
Narrows counseling content |
| 13 |
Advising about other inhibitors of CYP1A2 and another enzyme (CYP2C9/2C19/3A4) |
Expands beyond fluvoxamine but keeps inhibitor-class logic |
| 14 |
Advising about fluvoxamine altering therapeutic effect/adverse reaction |
Narrows counseling content |
| 15 |
Advising contraindication of pirfenidone with fluvoxamine |
Narrows counseling content |
| 16 |
Advising 6-fold exposure increase |
Narrows counseling content |
| 17 |
Adds numeric Cmax increase (2-fold) |
Narrows counseling content further |
| 18 |
Advising caution with strong CYP1A2 inhibitors; reduced clearance |
Narrows counseling content + another drug class |
| 19 |
Avoid administering strong CYP1A2 inhibitor |
Action-oriented dependent narrowing |
| 20 |
Discontinue strong CYP1A2 inhibitor |
Action-oriented dependent narrowing |
What is the likely patent landscape structure around US 7,816,383?
How this patent typically fits into the broader pirfenidone interaction IP cluster
US 7,816,383 is an interaction-management method patent. In the typical landscape for combination management of CYP-mediated interactions, patents tend to fall into three zones:
- Interaction-specific administration methods
- Avoiding a specific co-therapy (here, fluvoxamine) or discontinuing it before starting pirfenidone (this patent).
- Dose/regimen-specific maintenance around interaction management
- Incorporation of specific dosing patterns (2400/2403 mg/day; 800/801 mg TID with food).
- General CYP inhibitor caution methods
- Counseling about strong CYP1A2 inhibitors and other CYP enzymes (claims 13, 18-20).
This patent’s enforceability therefore is tied to real clinical workflows: interaction screening, discontinuation decisions, dosing documentation, and patient counseling.
Enforcement vectors
- Clinical practice documentation: counseling/discharge notes can map onto claims 11-20.
- Medication management protocols: hospital systems that require avoiding fluvoxamine and stopping before initiation align with claims 1, 5, 9-10.
- Medication titration/dosing: if systems administer the IPF standard maintenance dosing consistent with 2400 mg/day, claims 3-4, 7-8, and 11 strengthen alignment.
What are likely design-around strategies based on claim structure?
The claims’ differentiators suggest a handful of practical avoidance approaches for competitors or biosimilar/alternative prescribers. The risk profile depends on whether the avoidance is literal or only functional.
1) Keep fluvoxamine off the regimen during pirfenidone
- This matches the patent’s core requirement (avoidance).
- It can still trigger infringement if the method includes the claimed sequencing and/or counseling elements.
2) Avoid using the claimed “advising” content
- Claim 11 makes counseling content essential to that independent claim form.
- A party can attempt to avoid advising elements like “6-fold increase in exposure” or “contraindicated” phrasing. If counseling avoids those listed advice elements, the claim 11 form becomes harder to match literally.
3) Use different dosing that does not match the enumerated daily totals or TID strengths
- Claim dependents tie to 2400/2403 mg/day and 800/801 mg TID.
- Regimens outside those exact dose integers can reduce alignment with dependent claims 3-4, 7-8, 11 (though claim 1 and 5 are still broader if they do not require those exact doses).
4) Discontinuation timing outside the dependent windows
- Claims 9-10 specify within 1 month or within 2 weeks.
- But claim 5 still covers discontinuing fluvoxamine before starting pirfenidone, so timing alone is a weak design-around unless the practice also avoids satisfying claim 5’s sequencing constraints.
How does claim construction risk concentrate around “therapeutically effective amount”?
Claims 1 and 5 use “therapeutically effective amount” rather than exact dosing. This is a breadth amplifier. Even if a defendant changes dosing, they may still land in scope if pirfenidone is administered at doses used to treat IPF in practice.
The more defensible narrowing is achieved through claims that add exact dose values (2400/2403; 800/801 TID) or counseling elements (6-fold exposure, 2-fold Cmax).
Key takeaways for investors and product strategists
- US 7,816,383 is enforceable against interaction-management behaviors, not just prescriptions, because claims 11-20 include patient-advice content and exposure numeric statements.
- Core operational scope is avoidance of fluvoxamine co-administration during pirfenidone therapy, including sequencing via fluvoxamine discontinuation before starting pirfenidone (claims 1 and 5).
- Regimen specifics materially strengthen dependent claim alignment where real-world dosing matches 2400/2403 mg/day or 800/801 mg TID with food (claims 3-4, 7-8, and claim 11).
- Numeric exposure statements (6-fold exposure; 2-fold Cmax) appear as claim elements that can be directly mapped to patient counseling and labeling-like workflows (claims 16-17).
- Landscape positioning: this patent likely functions as a high-value blocker for any commercial play that relies on co-prescribing fluvoxamine during pirfenidone treatment or that standardizes counseling and discontinuation protocols consistent with the claimed language.
FAQs
1) Is US 7,816,383 limited to IPF?
No. IPF is explicitly required only in dependent claims 2 and 6 and in the independent claim 11 form. Claims 1 and 5 do not require IPF.
2) Does the patent require stopping fluvoxamine before starting pirfenidone?
Not for claim 1. Claim 1 requires avoiding co-administration. For claim 5, it requires discontinuing fluvoxamine first.
3) What dosing numbers matter most for claim coverage?
The dependents and claim 11 repeatedly use 2400 mg or 2403 mg/day and 800 or 801 mg three times per day with food.
4) Why do the “6-fold” and “2-fold” numbers matter?
They are written into the method via counseling elements. If patient advice includes those specific exposure conclusions, the method maps into claims 16-17.
5) Can avoiding fluvoxamine co-administration by itself eliminate risk?
Not necessarily. Even when fluvoxamine is avoided, risk persists if the practice also includes sequencing and/or the claimed counseling elements tied to claim 11-20.
References
[1] US 7,816,383 claims provided in the prompt (claims 1-20).
